Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caimiao Wei

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
The Lancet. Oncology|June 18, 2021
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyEric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, et al.
Journal of the National Cancer Institute|April 15, 2016
miR-141-Mediated Regulation of Brain Metastasis From Breast CancerBisrat G Debeb, Lara Lacerda, Simone Anfossi, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2016
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung CancerVassiliki Papadimitrakopoulou, J Jack Lee, Ignacio I Wistuba, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
The Lancet. Oncology|June 18, 2021
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyEric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, et al.
Journal of the National Cancer Institute|April 15, 2016
miR-141-Mediated Regulation of Brain Metastasis From Breast CancerBisrat G Debeb, Lara Lacerda, Simone Anfossi, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2016
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung CancerVassiliki Papadimitrakopoulou, J Jack Lee, Ignacio I Wistuba, et al.
Pageof 7